Regulatory Science & Clinical Research: Where Do We Stand (And Where Are We Going)?
It’s no secret that the FDA has recognized for years that the clinical trial system, with some of the worst return on investment (ROI) of any industry, is broken. Read…
Read More5 Bad Habits The Clinical Trial Community Needs To Break ASAP
The issue of clinical trial costs, both in terms of money and time, is big, complicated, and not at all new. The article discusses key persistent root causes and calls to…
Read MoreHistology-Agnostic Drug Development — Considering Issues Beyond the Tissie
*Presagia AI (OccamPoint Partner member)The landmark approvals of pembrolizumab for the treatment of patients whose tumors have high microsatellite instability and larotrectinib and entrectinib for those harbouring NTRK fusions, have marked the beginning…
Read More